FCN-342

Primary objective: To investigate the safety and tolerability of FCN-342 tablets after a single dose in healthy volunteers and patients with asymptomatic hyperuricemia and after multiple doses in patients with asymptomatic hyperuricemia. Secondary objective: To observe the pharmacokinetic and pharmacodynamic characteristics of FCN-342 in healthy volunteers and patients with asymptomatic hyperuricemia after a single dose of FCN-342 tablets; To observe the pharmacokinetic and pharmacodynamic characteristics of FCN-342 in patients with asymptomatic hyperuricemia after multiple doses of FCN-342 tablets; Exploratory objective: To preliminarily evaluate the effect of food on the human pharmacokinetic characteristics of FCN-342 tablets in patients with asymptomatic hyperuricemia; To evaluate the metabolism and excretion characteristics of FCN-342 tablets after oral administration in healthy volunteers. To determine FCN-342 and its main metabolites in urine and feces (if necessary); To conduct exploratory analysis to identify metabolites in plasma, urine and feces of healthy Chinese subjects after oral administration of FCN-342 tablets (if necessary). Explore the pharmacokinetic characteristics of the above metabolites (if necessary); evaluate the C-QTc, population PK/PD, and exposure-effect (ER) relationship in healthy volunteers/patients with asymptomatic hyperuricemia after oral administration of FCN-342 tablets.